CN-116617371-B - Application of recombinant type III humanized collagen in ovarian cancer treatment

Abstract

The invention belongs to the field of biological medicine, in particular to application of recombinant type III humanized collagen in ovarian cancer treatment, and more particularly relates to application of recombinant type III humanized collagen in preparation of a medicament for preventing and/or treating ovarian diseases, wherein the recombinant type III humanized collagen comprises n repeats of a sequence shown as SEQ ID No.1, n is an integer greater than or equal to 1, and when n is an integer greater than or equal to 2, the repeated sequences are directly connected. Research data show that the recombinant III type humanized collagen can obviously inhibit proliferation, migration, invasion and tumorigenicity of ovarian cancer cells, and the inhibition effect is more obvious under the condition of relatively high protein concentration, thereby providing a new thought for preparing medicines for preventing and/or treating ovarian diseases such as ovarian cancer and the like.

Inventors

• HU LINA
• YANG XIA
• LI HU
• ZENG HUI
• YOU SHUANG
• DONG XIAOJING

Assignees

• 山西锦波生物医药股份有限公司
• 重庆医科大学附属第二医院

Dates

Publication Date

20260508

Application Date

20230529

Claims (1)

1. 1. Use of recombinant type III humanized collagen in the manufacture of a medicament for treating ovarian cancer or for inhibiting proliferation, migration, invasion and/or neoplasia of ovarian cancer cells, wherein, The amino acid sequence of the recombinant III type humanized collagen is shown as SEQ ID No.3, and the ovarian cancer is ovarian epithelial tumor.

Description

Application of recombinant type III humanized collagen in ovarian cancer treatment Technical Field The invention belongs to the field of biological medicine, and in particular relates to an application of recombinant type III humanized collagen in ovarian cancer treatment. Background Ovarian cancer is a malignant tumor of ovarian tumor, and is a malignant tumor growing on the ovary, wherein 90% -95% of ovarian primary cancers, and 5% -10% of ovarian primary cancers at other parts are transferred to the ovary. Because the ovarian cancer lacks symptoms at early stage, the ovarian cancer is not specific even if the ovarian cancer has symptoms, and the screening effect is limited, the early diagnosis is difficult, 60% -70% of cases at the time of diagnosis are advanced, and the curative effect of advanced cases is usually poor. Therefore, although the incidence rate of ovarian cancer is lower than cervical cancer and endometrial cancer and is the third place of gynecological malignant tumor, the death rate exceeds the sum of cervical cancer and endometrial cancer, and the high-lying gynecological cancer is the first place and is the largest disease seriously threatening the health of women. Collagen is the most abundant protein in animals, accounting for about 30% of total protein, and plays an important role in physiological processes such as cell adhesion. Collagen has been widely used in the medical field because of its good biocompatibility and biodegradation safety. Up to now, most of the collagen used in various studies is derived from animal tissue and skin extracts. Collagen extracted from animals is generally poorly water-soluble and poorly processable, directly limiting the development of many potential uses for collagen. The collagen produced by the genetic engineering technology can effectively overcome the defects of the collagen from animal sources. The patent application with the application number of CN201811438582.6 and the name of 'polypeptide, its production method and application' describes the recombinant III type humanized collagen which has been studied and produced by the inventor of the present invention before, and has the characteristics of high water solubility and high biological activity. There is no report describing the link between recombinant type III humanized collagen and ovarian cancer treatment. Disclosure of Invention Problems to be solved by the invention The invention aims to evaluate the curative effect of the recombinant III type humanized collagen in the patent application with the application number of CN201811438582.6 in the aspect of ovarian cancer treatment, and particularly, the invention researches the influence of the recombinant III type humanized collagen on the proliferation, migration, invasion and tumorigenicity of ovarian cancer cells so as to achieve the aim of preventing and/or treating ovarian cancer. Solution for solving the problem The invention provides application of recombinant III type humanized collagen in preparing medicaments for preventing and/or treating ovarian diseases, wherein the recombinant III type humanized collagen comprises n repeats of a sequence shown in SEQ ID No.1, n is an integer greater than or equal to 1, and when n is an integer greater than or equal to 2, the repeated sequences are directly connected. Preferably, n is 1, 2, 3, 4,5, 6, 7, 8, 9, 10, 12, 14, 16, 20, 24, or 32. Further, the recombinant type III humanized collagen contains the sequence shown in SEQ ID No.2 or does not contain the sequence shown in SEQ ID No. 2. Still further, the recombinant type III humanized collagen comprises: a) The amino acid sequence of SEQ ID No. 3; b) An amino acid sequence having 90% identity to the amino acid sequence of SEQ ID No.3, which retains the ovarian disease therapeutic effect of the amino acid sequence of SEQ ID No. 3; c) An amino acid sequence of 1 or more amino acid residues added, substituted, deleted or inserted into the amino acid sequence of SEQ ID No.3, which retains the therapeutic effect of the amino acid sequence of SEQ ID No.3 on ovarian diseases, or D) An amino acid sequence encoded by a nucleotide sequence that hybridizes with an amino acid sequence encoding SEQ id No.3 under stringent conditions that preserve the therapeutic effect of the amino acid sequence of SEQ id No.3 on ovarian disease, said stringent conditions being medium-high, medium-high or very high stringency conditions. Further, the ovarian disease is ovarian cancer. Still further, according to the type of ovarian cancer, the ovarian cancer includes ovarian epithelial tumors, ovarian germ cell tumors, and ovarian chordal interstitial tumors. Further, the recombinant type III humanized collagen prevents and/or treats ovarian cancer by inhibiting the proliferation capacity of ovarian cancer cells, inhibiting the migration capacity of ovarian cancer cells, inhibiting the invasion capacity of ovarian cancer cells, and/or inhibiting the tumorigenicity c